latest news
event clips
2016/04/06
The First Triumph Case of Licensing Taiwan’s Advanced Medical Software Device Licensed to Chin...
2015/11/03
The First Medical Charity Event Featuring Thyroid Exams in Taiwan Substantially Benefits from ...
2015/09/18
Innovative Technology Avoids Unnecessary Needle Usage on Thyroid Cancer Detection ...
2015/08/22
The Swollen Neck on a College Student is Eventually Diagnosed as Thyroid Cancer...
2015/01/29
AmCad obtains Taiwan medical software license...
2014/04/23
AmCAD-UT® Detection has obtained the CE mark for marketing in the European Economic...
2014/04/11
AmCad BioMed Corporation Providing Computer-Aided Ultrasonic Cancer Diagnosis Product...
2014/04/03
AmCad’s Blue Ocean Strategy for CAD Systems to Develop Their Own Core-Technology Platform...
1/2
2017 Arab Health
2016 Medica
1/1
Corporate Overview
AmCad Milestones

Corporate Overview

  • AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015 (Ticker: 4188).
  • AmCad BioMed Corporation is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. The company has successfully developed and commercialized a series of the pioneering, first-in-the-world medical devices.
  • AmCad's strong pipeline includes AmCAD-UT (FDA, CE Mark and TFDA, for thyroid nodules analysis), AmCAD-UV (CE Mark, for classifying pulsatile), AmCAD-US (CE Mark, for backscattered signals analysis), AmCAD-UO (for obstructive sleep apnea detection), AmCAD-CA (for cytopathology analysis) and iSONO accessory (revolutionizing ultrasound imaging). The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid cancers, breast cancers, etc., and diseases, including liver fibrosis and obstructive sleep apnea.
  • AmCad's Blue Ocean Strategy for the CAD systems is to develop its own core-technology platforms by providing high value-added, state-of-the-art medical solutions targeting a wide variety of clinical applications and raising the global competition to a higher level. We are ready to make extensive contribution to the health and wellbeing of  humankind.
December-AmCad BioMed Corporation(AmCad) was founded.
2008
January-Transferred technology with exclusive authorization from National Taiwan University.
2009
June-Received “Important Emerging Strategic Industry” status approval letter by Industrial Development Bureau(IDB) of Ministry of Economic Affairs(MoEA)
July -Awarded Industrial Technology Development Program (TDP) Grant “Computer-assisted thyroid disease ultrasound diagnostic system” by MoEA
December -Identified as a company of the emerging medical health care industry in Taiwan by Industrial Development Bureau (IDB)
May-Received The 7th National Innovation Award
2010
May -Received the “Certificate of Manufacturer of Medical Devices” after its factory establishment
2011
November-Received GMP certification for Software Manufacturing
March -Awarded R&D project Grant, “Development of Calibration Method for Compatibility with Various US Machines”, by Taipei City Government
2012
February -Started to receive patent approvals for its core technologies in U.S., Singapore, Taiwan, etc
2013
September-Received Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award
October -Received U.S. FDA 510(k) clearance for AmCAD-UT Detection 2.0
November -Recommended by Industrial Development Bureau (IDB), MoEA as a qualified technology enterprise for IPO application
December -Listed on Taiwan’s Emerging Stock Market (Code: 4188)
April -Received CE Marking approval for AmCAD-UT Detection 2.0
2014
January -Received TFDA clearance for AmCAD-UT® Detection
2015
March -Listed on Taiwan’s OTC Stock Market (Code: 4188)
December -Received Silver Award of National Biotechnology and Medical Care Quality Award for AmCAD-UT® Detection
April -Received CE Marking approval for AmCAD-US
2016
April -Granted distribution right of China to Huajin Yike Pharmaceutical, based in Zhejiang Province, for AmCAD-UT® Detection with a US$5 million payment obligation
May-Received CE Marking approval for AmCAD-UV
June -Received TFDA clearance for upgrade version of AmCAD-UT® Detection
July-Received Go-Global Silver Medal Award of Taipei Biotechnology Award
July-Received Frost & Sullivan Taiwan Business Best Practice Award
December -Received Drug Research and Development Science and Technology Award for AmCAD-UT® Detection
December-Received the 13th National Innovation Award for AmCAD-CA
OPERATING TEAM
R&D Consultants

2016 National Innovation Award
President of Institute for Biotechnology and Medicine Industry presented National Innovation Award to Argon Chen, General Manager of AmCad BioMed Corporation.

2016 Drug Research and Development Science and Technology Award
Director of TFDA presented Drug Research and Development Science and Technology Award to Yi-Li Lee, Executive Director of AmCad BioMed Corporation.

2016 Frost & Sullivan Taiwan Excellence Awards

Frost & Sullivan presented 2016 Frost & Sullivan Taiwan Excellence Award to Jack Yang, Vice President of AmCad BioMed Corporation.

2016 Bio Taipei Awards

Deputy Mayors presented 2016 Bio Taipei Award to Yi -Li Lee, Executive Director of AmCad BioMed Corporation.

2015 Symbol of National Quality Award

Former Vice President presented Symbol of National Quality Award to Yi -Li Lee, Executive Director of AmCad BioMed Corporation.

2013 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award-Silver Award in Biomedical Group - AmCad BioMed Corporation

We appreciate the support and the recommendation from Epoch and the committee. AmCad keeps working on elevating the diagnostic accuracy and lowering the medical expense. We also anticipate that improvement of our CAD system can bring better performance to the world.

 

2013 Taiwan Healthcare and
Agricultural Biotech Industries
Innovation and Excellence Award

2010 the 7th National Innovation Award.

Former Vice President presented the award to C.C. Lee, Chairman of AmCad Biomed Corporation.

AmCad award-winning


2016 National Innovation Award


2016 Drug Research and Development Science and Technology Award


2016 Taiwan Business Best Practice Award


2016 Taipei Biotechnology Award


2015 Symbol of National Quality Award


2013 Taiwan Healthcare and Agricultural


2010 the 7th National Innovation Award.

AmCad software will assist physician improve diagnostic efficiency

Characteristic

AmCAD-UT® Detection uses statistical pattern recognition and quantification methods to perform analytical processing of images. The physician may process the image for detection of sonographic characteristics (i.e., hyperechoic foci, echogenicity, texture, margin, anechoic areas, taller than wide, tumor shape, and tumor size) with assistance of AmCAD-UT® Detection. AmCAD-UT® Detection provides more detailed information with quantification and visualization of the sonographic characteristics on thyroid nodule that may assist medical professionals in making their diagnostic decision.

  • FDA 510(k) 、CE Mark、TFDA Clearance
  • Patent-protected technologies - ​Tumor contour retrieving method、Quantification and imaging of tumor features、Muti-layer classifier
  • Differentiate between benign and malignant thyroid tumor using proprietary patented algorithms
  • Rapid digital reporting system
Please click the buttons to switch the image
AmCAD-UT®
Detection
Original Image

AmCAD-UT® Detection 2.2 Solution for Thyroid Ultrasound Image

Global Patent Protected:
U.S.、Europe、Taiwan、China、Southeast Asia

Select Category
  • Product-AmCAD-UT Detection
  • Product-AmCAD-UV
  • Product-AmCAD-US
  • Product-AmCAD-CA
  • Product-AmCAD-UO
  • Product-iSONO
  • Business Service
  • Other
RESET
SEND